Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder

NCT00694915
completedphase_2

Mycobacterium w in Patients With Severe Sepsis

NCT02330432
completedphase_2

A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer

NCT00680940
completedphase_1

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

NCT00694798
terminatedphase_2

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

NCT00525408

Clinical Trials (5)

Showing 5 of 5 trials
NCT00694915Phase 2

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder

Completed
NCT02330432Phase 2

Mycobacterium w in Patients With Severe Sepsis

Completed
NCT00680940Phase 2

A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer

Completed
NCT00694798Phase 1

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

Completed
NCT00525408Phase 2

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5